SCHEMBL6609571

SCHEMBL6609571

Cc1cccc(-c2ccc(C(=O)O)c3ccccc23)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
KDM4E B2RXH2 3/20 0.58
HPGD P15428 2/20 0.58
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
SORT1 Q99523 2/20 0.46
CCR1 P32246 1/20 0.46
CCR8 P51685 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
DHODH Q02127 1/20 0.45
HTR1A P08908 3/20 0.44
HTR1D P28221 3/20 0.44
HTR1B P28222 3/20 0.44
TGFBR1 P36897 2/20 0.44
TYMS P04818 1/20 0.43
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
APOBEC3A P31941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7847744 0.92 KDM4E (0.56) ALDH1A1KDM4EHPGDNR4A1NR4A2
SCHEMBL27887898 0.81 CDC25B (0.50) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL27887912 0.81 KDM4E (0.51) ALDH1A1KDM4EHPGDNR4A1NR4A2
SCHEMBL27887913 0.81 KDM4E (0.51) ALDH1A1KDM4EHPGDNR4A1NR4A2
SCHEMBL6605593 0.79 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDNR4A1NR4A2
SCHEMBL7849474 0.78 CCR1 (0.46) ALDH1A1KDM4EHPGDSORT1CCR1
SCHEMBL16277390 0.78 SORT1 (0.55) ALDH1A1KDM4EHPGDSORT1CCR1
SCHEMBL6606246 0.78 TDP1 (0.51) ALDH1A1KDM4EHPGDCCR1CCR8
SCHEMBL27903810 0.77 SMN1; SMN2 (0.48) ALDH1A1KDM4EHPGDNR4A1NR4A2
SCHEMBL27886900 0.76 ECE1 (0.51) ALDH1A1KDM4EHPGDNR4A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1190432-C Piperazing derivatives as 5-HT1B antagonists SMITHKLINE BEECHAM PLC (GB) 2005-02-23 CN disclosed
US-20040176388-A1 Piperazine derivatives as 5-HT1B antagonists SMITHKLINE BEECHAM P.I.C. 2004-09-09 US disclosed
US-6747030-B1 CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS SMITHKLINE BEECHAM P.L.C. (GB) 2004-06-08 US disclosed
EP-1216239-B1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-02-11 EP disclosed
CN-1399635-A Piperazing derivatives as 5-HT1B antagonists SMITHKLINE BEECHAM PLC (GB) 2003-02-26 CN disclosed
EP-1216239-A1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2002-06-26 EP disclosed
WO-2001023374-A1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176388-A1 Piperazine derivatives as 5-HT1B antagonists HTR1B, HTR2B, HTR2A ALDH1A1 500/4885KDM4E 2264/4885HPGD 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.